BE904831A - Composition d'activateur tissulaire du plasminogene. - Google Patents

Composition d'activateur tissulaire du plasminogene.

Info

Publication number
BE904831A
BE904831A BE0/216712A BE216712A BE904831A BE 904831 A BE904831 A BE 904831A BE 0/216712 A BE0/216712 A BE 0/216712A BE 216712 A BE216712 A BE 216712A BE 904831 A BE904831 A BE 904831A
Authority
BE
Belgium
Prior art keywords
amino acid
activator composition
tissue activator
plasminogen tissue
acid sequence
Prior art date
Application number
BE0/216712A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521704A external-priority patent/GB8521704D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of BE904831A publication Critical patent/BE904831A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Solution aqueuse parentérale d'un pH de 2 à 5 contenant du t-PA mono- ou bicaténaire qui a la séquence des aminoacides à laFig. 1 ou a la meme séquence des aminoacides, mais dont l'aminoacide à la position 245 à partir de l'extrémité N-terminale de la sérine est la valine au lieu de la méthionine, l'une ou l'autre séquence étant éventuellement exempte de l'un quelconque des trois premiers aminoacides ou comprenant éventuellement une préséquence de Gly-Ala-Arg supplémentaire N-terminale du polypeptide.
BE0/216712A 1985-05-28 1986-05-27 Composition d'activateur tissulaire du plasminogene. BE904831A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521704A GB8521704D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (1)

Publication Number Publication Date
BE904831A true BE904831A (fr) 1986-11-27

Family

ID=26289289

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/216712A BE904831A (fr) 1985-05-28 1986-05-27 Composition d'activateur tissulaire du plasminogene.

Country Status (22)

Country Link
US (1) US5112609A (fr)
AT (1) AT391812B (fr)
AU (1) AU569429B2 (fr)
BE (1) BE904831A (fr)
CA (1) CA1297008C (fr)
CH (1) CH664495A5 (fr)
DE (1) DE3617753A1 (fr)
DK (1) DK163174C (fr)
ES (1) ES8706443A1 (fr)
FI (1) FI85334C (fr)
FR (1) FR2593393B1 (fr)
GB (1) GB2176703B (fr)
GR (1) GR861365B (fr)
HU (1) HU200695B (fr)
IL (1) IL78937A (fr)
IT (1) IT1191925B (fr)
LU (1) LU86445A1 (fr)
NL (1) NL8601354A (fr)
NO (1) NO171344C (fr)
NZ (1) NZ216306A (fr)
PT (1) PT82647B (fr)
SE (1) SE462893B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185259A (en) * 1982-05-05 1993-02-09 Genentech, Inc. Truncated human tissue plasminogen activator
FI831484L (fi) 1982-05-05 1983-11-06 Genentech Inc Plasminogen aktivator foer maenskovaevnad
ZA833174B (en) * 1982-05-05 1984-08-29 Genentech Inc Human tissue plasminogen activator
WO1986005096A1 (fr) * 1985-03-06 1986-09-12 Survival Technology, Inc. Agents favorisant l'absorption de proteines
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
BE1001425A4 (fr) * 1986-05-12 1989-10-31 Wellcome Found Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8814604D0 (en) * 1988-06-20 1988-07-27 Wellcome Found Medicaments
WO1990001334A1 (fr) * 1988-08-05 1990-02-22 Codon Formules d'activateur du plasminogene a base d'aspartate
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
GB9000629D0 (en) * 1990-01-11 1990-03-14 Porton Prod Ltd Tissue plasminogen activator
PT786257E (pt) * 1992-06-03 2003-12-31 Genentech Inc Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
DK0827751T3 (da) * 1996-09-06 2003-03-31 Chemo Sero Therapeut Res Inst Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
NZ589557A (en) * 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
ES2552337T3 (es) 2009-03-03 2015-11-27 Grifols Therapeutics Inc. Procedimientos para la preparación de plasminógeno

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (fr) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4314994A (en) * 1979-07-27 1982-02-09 Pierre Fabre S.A. Process for obtaining a plasminogen activator
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
ZA831399B (en) * 1982-03-05 1984-02-29 Health Lab Service Board New fibrinolytic enzymes and methods for their production and pharmaceutical compositions containing them
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
NL191755C (nl) * 1982-10-29 1996-07-02 Mitsui Toatsu Chemicals Plasminogeenactivator en trombolytisch middel.
EP0112122B1 (fr) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Activateur de plasminogène
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (fr) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha Solution aqueuse d'un activateur tissulaire du plasminogène dissous à une concentration élevée et un procédé d'obtention
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE59009964D1 (de) * 1989-09-13 1996-01-25 Rieter Ag Maschf Verfahren zum Starten eines Arbeitsablaufs eines Bedienungsautomaten an einer Textilmaschine

Also Published As

Publication number Publication date
FR2593393B1 (fr) 1989-06-02
HUT42330A (en) 1987-07-28
AU5796586A (en) 1986-12-04
HU200695B (en) 1990-08-28
ATA141186A (de) 1990-06-15
NZ216306A (en) 1989-10-27
ES555352A0 (es) 1987-07-01
CA1297008C (fr) 1992-03-10
IL78937A (en) 1990-11-29
NO171344C (no) 1993-03-03
IT1191925B (it) 1988-03-31
NO862095L (no) 1986-12-01
GB2176703B (en) 1988-12-07
LU86445A1 (fr) 1986-12-05
DE3617753C2 (fr) 1988-06-30
IT8648064A0 (it) 1986-05-27
FI862226A0 (fi) 1986-05-27
DK163174B (da) 1992-02-03
DK163174C (da) 1992-06-22
FR2593393A1 (fr) 1987-07-31
US5112609A (en) 1992-05-12
NO171344B (no) 1992-11-23
DK246886D0 (da) 1986-05-27
DE3617753A1 (de) 1986-12-04
PT82647B (pt) 1989-01-30
GB2176703A (en) 1987-01-07
GB8612781D0 (en) 1986-07-02
FI85334C (fi) 1992-04-10
PT82647A (en) 1986-06-01
NL8601354A (nl) 1986-12-16
DK246886A (da) 1986-11-29
ES8706443A1 (es) 1987-07-01
FI85334B (fi) 1991-12-31
AT391812B (de) 1990-12-10
CH664495A5 (de) 1988-03-15
SE462893B (sv) 1990-09-17
FI862226L (fi) 1986-11-29
GR861365B (en) 1986-09-29
IL78937A0 (en) 1986-09-30
SE8602404D0 (sv) 1986-05-27
AU569429B2 (en) 1988-01-28
SE8602404L (sv) 1986-11-29

Similar Documents

Publication Publication Date Title
BE904831A (fr) Composition d'activateur tissulaire du plasminogene.
ATE108186T1 (de) Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen.
PT788509E (pt) Derivados peptidicos terapeuticos
ATE123949T1 (de) B-ketten-analoge des von blutplättchen abstammenden wachstumsfaktors und verfahren zu deren homogener herstellung.
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
BE904830A (fr) Nouvelle composition d'activateur tissulaire du plasminogene.
ES2125718T3 (es) Purificacion de corriente de subproducto en la preparacion de poliesteres a base de 1,3-propanodiol.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
DE3588249D1 (de) Methode zur Herstellung von menschlichen Wachstumshormonen
LV12000A (lv) Olbaltumviela ar uratoksidazes aktivitati un tas iegusana
DE3667490D1 (de) Herstellung von peptiden mit c-terminalem prolinamid.
SE8901552D0 (sv) Acid addition salts of amidated or glycine, their preparation and use
DK1897552T3 (da) Polymer-konjugeret glycosyleret neublastin
DK0639202T3 (da) Stabil polypeptidsammensætning
IL88963A0 (en) Synthetic peptides and mixtures thereof for detecting hiv antibodies
KR950005325A (ko) 제약 조성물
ES2081797T3 (es) Aminoacidos y derivados peptidicos de 1,4-bis((aminoalquil e hidroxiaminoalquil)amino)-5,8-dihidroxiantraquinonas.
SE8500093L (sv) Urokinasderivat
ATE191923T1 (de) Interleukine-6 mutante mit verbesserter biologischer aktivität im vergleich zu wildtyp il-6
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
ATE93731T1 (de) Protein enthaltende waesserige loesungen.
PT93154A (pt) Pentamidine solutions
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
KR950018049A (ko) 사람 dna 토포이소머라제 제i형의 돌연변이체 단백질
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THE WELLCOME FOUNDATION LTD

Effective date: 19950531